日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neutrophil activation identifies patients with active polyarticular gout

中性粒细胞活化可识别活动性多关节痛风患者。

Vedder, D; Gerritsen, M; Duvvuri, B; van Vollenhoven, R F; Nurmohamed, M T; Lood, C

IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

IgG4:IgG RNA 比值可区分肉芽肿性多血管炎的活动期和缓解期:一种新的疾病活动性标志物?一项横断面和纵向研究

Al-Soudi, A; Doorenspleet, M E; Esveldt, R E; Burgemeister, L T; Hak, A E; van den Born, B J H; Tas, S W; van Vollenhoven, R F; Klarenbeek, P L; de Vries, N

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

皮下注射贝利木单抗治疗抗双链DNA抗体阳性、低补体血症系统性红斑狼疮患者的疗效和安全性

Doria, A; Stohl, W; Schwarting, A; Okada, M; Scheinberg, M; van Vollenhoven, R; Hammer, A E; Groark, J; Bass, D; Fox, N L; Roth, D; Gordon, D

Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky

中轴型脊柱关节炎的性别差异:女性并非那么幸运

Rusman, T; van Vollenhoven, R F; van der Horst-Bruinsma, I E

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

在既往未接受过DMARD治疗且预后不良的早期活动性类风湿关节炎患者中,塞妥珠单抗聚乙二醇联合剂量优化的甲氨蝶呤:一项随机、双盲、安慰剂对照的III期研究的1年结果

Emery, P; Bingham, C O 3rd; Burmester, G R; Bykerk, V P; Furst, D E; Mariette, X; van der Heijde, D; van Vollenhoven, R; Arendt, C; Mountian, I; Purcaru, O; Tatla, D; VanLunen, B; Weinblatt, M E

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists

言行一致?风湿病学家对类风湿性关节炎指南遵循情况的探索性多层次研究

Lesuis, N; den Broeder, A A; Hulscher, M E J L; van Vollenhoven, R F

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort

系统性红斑狼疮国际合作诊所队列中,系统性红斑狼疮诊断前或诊断后早期发生的心血管事件

Urowitz, M B; Gladman, D D; Anderson, N M; Su, J; Romero-Diaz, J; Bae, S C; Fortin, P R; Sanchez-Guerrero, J; Clarke, A; Bernatsky, S; Gordon, C; Hanly, J G; Wallace, D J; Isenberg, D; Rahman, A; Merrill, J; Ginzler, E; Alarcón, G S; Fessler, B F; Petri, M; Bruce, I N; Khamashta, M; Aranow, C; Dooley, M; Manzi, S; Ramsey-Goldman, R; Sturfelt, G; Nived, O; Steinsson, K; Zoma, A; Ruiz-Irastorza, G; Lim, S; Kalunian, K C; Ỉnanç, M; van Vollenhoven, R; Ramos-Casals, M; Kamen, D L; Jacobsen, S; Peschken, C; Askanase, A; Stoll, T

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

贝利木单抗联合标准治疗治疗系统性红斑狼疮患者的长期器官损伤累积和安全性

Bruce, I N; Urowitz, M; van Vollenhoven, R; Aranow, C; Fettiplace, J; Oldham, M; Wilson, B; Molta, C; Roth, D; Gordon, D

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

塞妥珠单抗聚乙二醇治疗类风湿性关节炎安全性概况更新:临床试验的综合分析

Bykerk, V P; Cush, J; Winthrop, K; Calabrese, L; Lortholary, O; de Longueville, M; van Vollenhoven, R; Mariette, X

Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial

阿塔西普联合利妥昔单抗治疗类风湿性关节炎的安全性和有效性:一项 II 期随机、双盲、安慰剂对照的初步试验

van Vollenhoven, R F; Wax, S; Li, Y; Tak, P P